Suppr超能文献

经衣壳修饰的重组 AAV2 载体高效转导人源单核细胞来源的树突状细胞。

High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.

机构信息

Division of Cellular and Molecular Therapy, Department of Pediatrics, University of Florida, College of Medicine, Gainesville, FL, USA.

出版信息

Vaccine. 2012 Jun 6;30(26):3908-17. doi: 10.1016/j.vaccine.2012.03.079. Epub 2012 Apr 10.

Abstract

Phosphorylation of surface-exposed tyrosine residues negatively impacts the transduction efficiency of recombinant AAV2 vectors. Pre-treatment of cells with specific cellular serine/threonine kinase inhibitors also significantly increased the transduction efficiency of AAV2 vectors. We reasoned that site-directed mutagenesis of surface-exposed serine residues might allow the vectors to evade phosphorylation and thus lead to higher transduction efficiency. Each of the 15 surface-exposed serine (S) residues was substituted with valine (V) residues, and the transduction efficiency of three of these mutants, S458V, S492V and S662V, was increased by up to ≈ 20-fold in different cell types. The S662V mutant was efficient in transducing human monocyte-derived dendritic cells (moDCs), a cell type not readily amenable to transduction by the conventional AAV vectors, and did not induce any phenotypic changes in these cells. Recombinant S662V-AAV2 vectors encoding a truncated human telomerase (hTERT) gene were generated and used to stimulate cytotoxic T cells (CTLs) against target cells. S662V-AAV2-hTERT vector-transduced DCs resulted in rapid, specific T-cell clone proliferation and generation of robust CTLs, which led to specific cell lysis of K562 cells. These studies suggest that high-efficiency transduction of moDCs by serine-modified AAV2 vectors is feasible, which supports the potential utility of these vectors for future human DCs vaccine studies.

摘要

表面暴露的酪氨酸残基的磷酸化会负向影响重组 AAV2 载体的转导效率。用特定的细胞丝氨酸/苏氨酸激酶抑制剂预处理细胞也显著提高了 AAV2 载体的转导效率。我们推测,表面暴露的丝氨酸残基的定点突变可能使载体逃避磷酸化,从而导致更高的转导效率。将 15 个表面暴露的丝氨酸(S)残基中的每一个都突变为缬氨酸(V)残基,其中三个突变体 S458V、S492V 和 S662V 的转导效率在不同的细胞类型中提高了约 20 倍。S662V 突变体有效地转导人单核细胞衍生的树突状细胞(moDC),而这种细胞类型不易被传统的 AAV 载体转导,并且不会在这些细胞中引起任何表型变化。生成了编码截短的人端粒酶(hTERT)基因的重组 S662V-AAV2 载体,并用于刺激针对靶细胞的细胞毒性 T 细胞(CTL)。S662V-AAV2-hTERT 载体转导的 DC 导致 T 细胞克隆迅速、特异性增殖,并产生强大的 CTL,从而导致 K562 细胞的特异性细胞裂解。这些研究表明,通过丝氨酸修饰的 AAV2 载体对 moDC 的高效转导是可行的,这支持了这些载体在未来人类 DC 疫苗研究中的潜在应用。

相似文献

引用本文的文献

1
Strategies to improve safety profile of AAV vectors.改善腺相关病毒载体安全性的策略。
Front Mol Med. 2022 Nov 1;2:1054069. doi: 10.3389/fmmed.2022.1054069. eCollection 2022.
10
Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors.用于靶向和提高腺相关病毒载体效力的衣壳修饰
Mol Ther Methods Clin Dev. 2019 Jan 26;12:248-265. doi: 10.1016/j.omtm.2019.01.008. eCollection 2019 Mar 15.

本文引用的文献

3
Recent developments in cancer vaccines.癌症疫苗的最新进展。
J Immunol. 2011 Feb 1;186(3):1325-31. doi: 10.4049/jimmunol.0902539.
4
Immunologic basis of vaccine vectors.疫苗载体的免疫学基础。
Immunity. 2010 Oct 29;33(4):504-15. doi: 10.1016/j.immuni.2010.10.004.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验